Leerink Partners maintains Outperform rating on Lexeo Therapeutics, $15 price target

Leerink Partners maintained their Outperform rating on Lexeo Therapeutics's stock with a price target of $15.00.The price target implies an upside of 268.6% from the Sep 22 close of $4.07.Key takeaways from the analyst noteStrong Clinical Data and First-Mover Advantage: Lexeo Therapeutics has demon…